Axial spondyloarthritis (axSpA) and diffuse idiopathic skeletal hyperostosis (DISH) involve tendon and ligament ossification showing similarity on spinal radiographs. Differentiating axSpA from DISH facilitates proper treatment and improves inflammatory pain; however, the overlap between axSpA and DISH delays its diagnosis.
{"title":"Axial Spondyloarthritis in Diffuse Idiopathic Skeletal Hyperostosis","authors":"K. Aso, M. Kato, T. Atsumi","doi":"10.3899/jrheum.220082","DOIUrl":"https://doi.org/10.3899/jrheum.220082","url":null,"abstract":"Axial spondyloarthritis (axSpA) and diffuse idiopathic skeletal hyperostosis (DISH) involve tendon and ligament ossification showing similarity on spinal radiographs. Differentiating axSpA from DISH facilitates proper treatment and improves inflammatory pain; however, the overlap between axSpA and DISH delays its diagnosis.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"41 1","pages":"956 - 957"},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74685327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Amezcua-Guerra, M. Mora-Ramírez, G. Vancini, V. Jiménez-Rojas, R. Márquez-Velasco
Systemic sclerosis (SSc) is a devastating disease associated with lung involvement, primarily interstitial lung disease (ILD) and pulmonary hypertension (PH).1 Although computed tomography (CT) and right heart catheterization accurately identify cardiopulmonary injury,2 their high cost and technical complexity make them inaccessible to most nonspecialized health centers. Thus, the timely detection of lung involvement remains a challenge in real-world settings.
{"title":"Fibroblast Growth Factor 23 Levels in Pulmonary Involvement Associated With Systemic Sclerosis: A Proof-of-concept Study","authors":"L. Amezcua-Guerra, M. Mora-Ramírez, G. Vancini, V. Jiménez-Rojas, R. Márquez-Velasco","doi":"10.3899/jrheum.211156","DOIUrl":"https://doi.org/10.3899/jrheum.211156","url":null,"abstract":"Systemic sclerosis (SSc) is a devastating disease associated with lung involvement, primarily interstitial lung disease (ILD) and pulmonary hypertension (PH).1 Although computed tomography (CT) and right heart catheterization accurately identify cardiopulmonary injury,2 their high cost and technical complexity make them inaccessible to most nonspecialized health centers. Thus, the timely detection of lung involvement remains a challenge in real-world settings.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"2 1","pages":"542 - 544"},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76079623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There is increasing evidence of racial and ethnic disparities in the evaluation and treatment of people with psoriasis (PsO) and psoriatic arthritis, and inadequate racial/ethnic diversity in psoriatic disease (PsD) research. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2021 annual meeting, a program focusing on diversity, equity, and inclusion (DEI) was presented to highlight known health and healthcare disparities in PsD. There is limited understanding of the prevalence and severity of PsD and how it affects quality of life among racial/ethnic minorities with PsD. Educational gaps and lack of diversity in our dermatology workforce may be contributing to challenges in appropriately diagnosing and treating PsO in darker skin types. Racial/ethnic minorities are also inadequately represented in clinical research, including trial recruitment and participation, for PsD. A panel of patient research partners, researchers, and clinicians ended the session with a broad discussion on how GRAPPA can better ensure racial/ethnic DEI in their educational, research, and clinical missions.
{"title":"Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases.","authors":"J. Takeshita, J. Chau, K. Callis Duffin, N. Goel","doi":"10.3899/jrheum.211330","DOIUrl":"https://doi.org/10.3899/jrheum.211330","url":null,"abstract":"There is increasing evidence of racial and ethnic disparities in the evaluation and treatment of people with psoriasis (PsO) and psoriatic arthritis, and inadequate racial/ethnic diversity in psoriatic disease (PsD) research. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2021 annual meeting, a program focusing on diversity, equity, and inclusion (DEI) was presented to highlight known health and healthcare disparities in PsD. There is limited understanding of the prevalence and severity of PsD and how it affects quality of life among racial/ethnic minorities with PsD. Educational gaps and lack of diversity in our dermatology workforce may be contributing to challenges in appropriately diagnosing and treating PsO in darker skin types. Racial/ethnic minorities are also inadequately represented in clinical research, including trial recruitment and participation, for PsD. A panel of patient research partners, researchers, and clinicians ended the session with a broad discussion on how GRAPPA can better ensure racial/ethnic DEI in their educational, research, and clinical missions.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77344174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rituximab (RTX), a chimeric monoclonal antibody against B cell antigen CD20, has been used in patients with recalcitrant juvenile idiopathic arthritis ( JIA) with some efficacy.1,2 The resetting of peripheral B cells promoted by RTX represents quite an interesting option in autoimmune diseases such as JIA, not only for the immediate effect but also for the possible use of other therapies that might be necessary to achieve disease control.
{"title":"Tumor Necrosis Factor-α Inhibition Before and After Rituximab Treatment in Juvenile Idiopathic Arthritis: What Shall We Expect? A Pilot Study","authors":"A. Marino, F. Orsini, F. Pregnolato, R. Cimaz","doi":"10.3899/jrheum.211039","DOIUrl":"https://doi.org/10.3899/jrheum.211039","url":null,"abstract":"Rituximab (RTX), a chimeric monoclonal antibody against B cell antigen CD20, has been used in patients with recalcitrant juvenile idiopathic arthritis ( JIA) with some efficacy.1,2 The resetting of peripheral B cells promoted by RTX represents quite an interesting option in autoimmune diseases such as JIA, not only for the immediate effect but also for the possible use of other therapies that might be necessary to achieve disease control.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"33 1","pages":"654 - 656"},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86991998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The human microbiome, which consists of the microbial communities inhabiting the human body, has sparked growing excitement in both basic research and clinical practice.1,2 Gut microbiota, in particular, has been considered a major environmental factor in modulating immune responses in autoimmune diseases (ADs).3,4.
{"title":"Alterations of Plasma Microbiome: A Potentially New Perspective to the Dysbiosis in Systemic Lupus Erythematosus?","authors":"Yudong Liu, Fei Xiao, Rui Zhang, Xuan Zhang","doi":"10.3899/jrheum.220023","DOIUrl":"https://doi.org/10.3899/jrheum.220023","url":null,"abstract":"The human microbiome, which consists of the microbial communities inhabiting the human body, has sparked growing excitement in both basic research and clinical practice.1,2 Gut microbiota, in particular, has been considered a major environmental factor in modulating immune responses in autoimmune diseases (ADs).3,4.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"12 1","pages":"549 - 551"},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82122290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Janus kinase inhibitors ( JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis. A previous noninferiority surveillance study of patients aged > 50 years with rheumatoid arthritis and ≥ 1 additional cardiac risk factor raised a number of safety concerns. This review focuses on available safety data from peer-reviewed publications, as well as the most recent presentations from major conferences highlighting JAKi-associated adverse effects. The safety data for several types of JAKi are reviewed. The latest available safety data for tofacitinib, upadacitinib, filgotinib, deucravacitinib, and brepocitinib is presented. In addition, the findings from the oral surveillance study will be discussed to put safety concerns into context.
{"title":"Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis.","authors":"P. Nash","doi":"10.3899/jrheum.211329","DOIUrl":"https://doi.org/10.3899/jrheum.211329","url":null,"abstract":"Janus kinase inhibitors ( JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis. A previous noninferiority surveillance study of patients aged > 50 years with rheumatoid arthritis and ≥ 1 additional cardiac risk factor raised a number of safety concerns. This review focuses on available safety data from peer-reviewed publications, as well as the most recent presentations from major conferences highlighting JAKi-associated adverse effects. The safety data for several types of JAKi are reviewed. The latest available safety data for tofacitinib, upadacitinib, filgotinib, deucravacitinib, and brepocitinib is presented. In addition, the findings from the oral surveillance study will be discussed to put safety concerns into context.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86244660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The ability to visualize musculoskeletal structures with high-resolution ultrasound is an asset to understanding the complexity of psoriatic arthritis (PsA). During the 2021 Annual Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) meeting, 3 topics were presented and discussed in the ultrasound workshop: (1) the progress on the Diagnostic Ultrasound Enthesitis Tool (DUET) project; (2) the sonographic evaluation of joints in PsA-GRAPPA joint project; and (3) extrasynovial lesions in PsA. The ultrasound group aims to develop sonographic tools that are feasible and can be used in standard care to diagnose PsA early. The discussions around these topics will shape the group's work toward developing a composite index to diagnose PsA early.
{"title":"Toward a Sonographic Composite Index for Diagnosis in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.","authors":"S. Aydın, L. Eder, G. Kaeley","doi":"10.3899/jrheum.211339","DOIUrl":"https://doi.org/10.3899/jrheum.211339","url":null,"abstract":"The ability to visualize musculoskeletal structures with high-resolution ultrasound is an asset to understanding the complexity of psoriatic arthritis (PsA). During the 2021 Annual Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) meeting, 3 topics were presented and discussed in the ultrasound workshop: (1) the progress on the Diagnostic Ultrasound Enthesitis Tool (DUET) project; (2) the sonographic evaluation of joints in PsA-GRAPPA joint project; and (3) extrasynovial lesions in PsA. The ultrasound group aims to develop sonographic tools that are feasible and can be used in standard care to diagnose PsA early. The discussions around these topics will shape the group's work toward developing a composite index to diagnose PsA early.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84513281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There has been a resurgence of interest in defining the axial inflammation component of psoriatic arthritis (PsA) since recent randomized controlled trials (RCTs) raised the possibility that this entity may respond differentially to therapeutics compared to patients with axial spondyloarthritis. A workshop was conducted during the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis annual meeting to review the literature on diagnosing PsA and to determine which criteria might be most appropriate. There was quite strong agreement that magnetic resonance imaging (MRI) had an important role to play in helping to define axial inflammation in PsA and that a data-driven methodology for generating optimal MRI quantitative cut-offs for lesions in the sacroiliac joints and/or spine that reflect imaging typical of axial inflammation in PsA would be most desirable.
{"title":"What Constitutes a Positive MRI for Clinical Trial Recruitment of Psoriatic Arthritis Patients With Axial Involvement?","authors":"W. Maksymowych, M. Østergaard","doi":"10.3899/jrheum.211340","DOIUrl":"https://doi.org/10.3899/jrheum.211340","url":null,"abstract":"There has been a resurgence of interest in defining the axial inflammation component of psoriatic arthritis (PsA) since recent randomized controlled trials (RCTs) raised the possibility that this entity may respond differentially to therapeutics compared to patients with axial spondyloarthritis. A workshop was conducted during the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis annual meeting to review the literature on diagnosing PsA and to determine which criteria might be most appropriate. There was quite strong agreement that magnetic resonance imaging (MRI) had an important role to play in helping to define axial inflammation in PsA and that a data-driven methodology for generating optimal MRI quantitative cut-offs for lesions in the sacroiliac joints and/or spine that reflect imaging typical of axial inflammation in PsA would be most desirable.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74872272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. V. van Mens, G. Ayan, L. Coates, Roxana Coras, Dimitri L F Silva, Sebastián Herrera, A. Ishchenko, H. Jethwa, H. Johnsson, David Simon, A. Vivekanantham, F. Proft
At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting, a separate group was created (Young-GRAPPA) to address the challenges of young researchers and physicians beginning their careers. This paper presents the initial organizational framework and different components and aims of this group. We were able to enroll over 50 young researchers as a result of this meeting.
{"title":"Young-GRAPPA at the Annual GRAPPA Meeting: Presentation of a New Group Within GRAPPA and Its Vision.","authors":"L. V. van Mens, G. Ayan, L. Coates, Roxana Coras, Dimitri L F Silva, Sebastián Herrera, A. Ishchenko, H. Jethwa, H. Johnsson, David Simon, A. Vivekanantham, F. Proft","doi":"10.3899/jrheum.211327","DOIUrl":"https://doi.org/10.3899/jrheum.211327","url":null,"abstract":"At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting, a separate group was created (Young-GRAPPA) to address the challenges of young researchers and physicians beginning their careers. This paper presents the initial organizational framework and different components and aims of this group. We were able to enroll over 50 young researchers as a result of this meeting.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85147696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Why Should It Be Different From the Other Side? A Parent and Pediatrician’s Perspective of a Child With Kawasaki Disease","authors":"K. Gunasuntharam","doi":"10.3899/jrheum.211159","DOIUrl":"https://doi.org/10.3899/jrheum.211159","url":null,"abstract":"","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":"83 1","pages":"333 - 333"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88758673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：